Alvotech Welcomes Stelara Biosimilar Into Phase III Development

Joins Alvotech’s Biosimilar Humira Candidate

Alvotech has announced two studies running in parallel for the firm’s AVT04 ustekinumab biosimilar referencing Janssen’s $7.7bn Stelara treatment for autoimmune diseases, including a Phase III comparative study.

Spacecraft
Alvotech has launched two clinical trials • Source: Shutterstock

Alvotech has pushed its second biosimilar into Phase III clinical study development, the Icelandic firm’s AVT04 ustekinumab product referencing Janssen’s $7.7bn Stelara treatment for autoimmune diseases.

The first patient has been dosed in the firm’s AVT04-GL-301 comparative study, which aims to demonstrate therapeutic equivalence with Stelara...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.